On September 30, 2020, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of new Procedures for CADTH Drug Reimbursement Reviews (updated October 29, 2020), which harmonize procedures under CADTH’s drug reimbursement review pathways (Common Drug Review, pan-Canadian Oncology Drug Review, and Interim Plasma Protein Product Review). Notable highlights include the opportunity for drug manufacturers to comment on draft review reports; posting of draft recommendations for stakeholder feedback; and introduction of categories in the reconsideration process to promote flexibility.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
CDA–AMC (formerly CADTH) announces several pilot projects, including Target Zero initiative
CADTH is now known as Canada’s Drug Agency (CDA-AMC or CDA). Its mandate extends beyond CADTH’s mandate.Read More -
PMPRB releases Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines
On June 26, 2024, the Patented Medicine Prices Review Board (PMPRB) released a Discussion Guide for its Phase 2 Consultations on its New Guidelines.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More